Resistance to systemic drug therapies is a major reason for the failure of anti-cancer therapies. 21
Introduction 40
According to Globocan [1], there "were 14.1 million new cancer cases, 8.2 million cancer 41 deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 42 worldwide." Despite substantial improvements over recent decades, the prognosis for many 43 cancer patients remains unacceptably poor. The outlook is particularly grim for patients that are 44 diagnosed with disseminated (metastatic) disease who cannot be successfully treated by local 45 treatment (surgery, radiotherapy) and depend on systemic drug therapy, because the success of 46 systemic therapies is typically limited by the occurrence of therapy resistance [2] [3] [4] . 47
Drug efflux mediated by transporters including ATP-binding cassette (ABC) transporters has 48 been shown to play a crucial role in cancer cell drug resistance [2, 5] . ABCB1 (also known as 49
Results 142
Nanoparticle size, polydispersity and drug load 143 HSA nanoparticles were prepared by desolvation as previously described [13] [14] [15] [16] [17] . The 144 nanoparticles were stabilised by the crosslinking of free amino groups present in albumin. Three 145 different nanoparticle preparations were produced using glutaraldehyde at amounts that 146 corresponded to a theoretical cross-linking of 40% (HSA 40% nanoparticles), 100% (HSA 147 100% nanoparticles), or 200% (HSA 200% nanoparticles) of the amino groups that are 148 available in the HSA molecules. A non-stabilised (0% cross-linking) formulation was used as 149 a control. The resulting particle sizes and polydispersity indices are shown in Table 1 . HSA(0%) 150 nanoparticles displayed a large particle size of almost 1 µm range and a high polydispersity of 151 0.5, confirming that no stable nanoparticles had formed (Table 1 ). The three HSA nanoparticle 152 preparations stabilised by the different glutaraldehyde concentrations displayed similar 153 diameters between 460 and 500 nm and polydispersity indices in the range of 0.153 and 0.213 154 indicating a narrow but not monodisperse size distribution (Table 1) . 155
While HSA(40%), HSA(100%), and HSA(200%) nanoparticles displayed similar drug loads 156 between 152 and 191 µg doxorubicin/ mg nanoparticle, HSA(0%) nanoparticles had bound 157 371 µg doxorubicin/ mg HSA (Table 1) . This probably reflected the higher accessibility of 158 doxorubicin binding sites, which are known to be available on HSA [25] , in HSA molecules in 159 solution compared to the accessible binding sites available in HSA nanoparticles. 160 161 162
Doxorubicin sensitivity of the used neuroblastoma cell lines 163
The parental neuroblastoma cell line UKF-NB-3 and its doxorubicin-(UKF-NB-3 r DOX 20 ) and 164 vincristine-adapted (UKF-NB-3 r VCR 1 ) sub-lines substantially differed in their doxorubicin 165 sensitivity ( Figure 1 ). UKF-NB-3 displayed the lowest doxorubicin IC50 (3.8 ng/mL). UKF-166 NB-3 r VCR 1 was 4-fold more resistant to doxorubicin than UKF-NB-3 (doxorubicin IC50: 167 15.5 ng/mL). UKF-NB-3 r DOX 20 showed the highest doxorubicin IC50 (89.0 ng/mL) resulting 168 in a 23-fold increase in doxorubicin resistance compared to UKF-NB-3 (Figure 1, Suppl. Table  169 1). 170 171
Effects of doxorubicin-loaded nanoparticles on neuroblastoma cells 172
The effects of doxorubicin applied in solution or incorporated into HSA(0%), HSA(40%), 173 HSA(100%), or HSA(200%) nanoparticles on neuroblastoma cell viability are shown in Figure  174 2. The numerical values are presented in Suppl. Table 1 . Empty control nanoparticles did not 175 affect cell viability in the investigated concentrations. 176
In the neuroblastoma cell line UKF-NB-3, the nanoparticle preparations displayed similar 177 activity as doxorubicin solution, with doxorubicin-loaded HSA(40%), HSA(100%), and 178 HSA(200%) nanoparticles potentially showing a trend towards a slightly increased activity 179 ( Figure 2 ). However, the differences did not reach statistical significance. Similar results were 180 obtained in the doxorubicin-adapted UKF-NB-3 sub-line UKF-NB-3 r DOX 20 , although the 181 difference between doxorubicin-loaded HSA(200%) nanoparticles and doxorubicin solution 182 reached statistical significance ( Figure 2) . Notably, non-stabilised doxorubicin-bound 183 HSA(0%) nanoparticles differed in their relative activity and did not reduce UKF-NB-3 r DOX 20 184 viability by 50% within the observed concentration range up to 200 ng/mL. The vincristine-adapted UKF-NB-3 sub-line UKF-NB-3 r VCR 1 displayed decreased 186 doxorubicin sensitivity. However, doxorubicin-loaded HSA(40%), HSA(100%), and 187 HSA(200%) nanoparticles displayed a higher relative potency compared to doxorubicin 188 solution in UKF-NB-3 r VCR 1 (Figure 2 In UKF-NB-3 r DOX 20 cells, addition of zosuquidar resulted in an increased sensitivity to free 232 doxorubicin ( Figure 4 ). The doxorubicin IC50 decreased by 2.5-fold from 91 ng/mL in the 233 absence of zosuquidar to 37 ng/mL in the presence of zosuquidar, but not to the level of UKF-234 NB-3 cells (4.6 ng/mL) (Suppl. Table 2 ). This confirmed that ABCB1 is one among multiple 235 resistance mechanisms that contribute to the doxorubicin resistance phenotype observed in adaptation of UKF-NB-3 r VCR 1 cells to vincristine, a tubulin-binding agent with an anti-cancer 274 mechanism of action that is not related to that of the topoisomerase II inhibitor doxorubicin, did not result in the acquisition of changes that confer doxorubicin resistance beyond ABCB1 276 expression [2, 20, 30, 31] . This indicates that the personalised use of nanoparticle-encapsulated 277 transporter substrates will benefit from the use of biomarkers that indicate drug-specific 278 resistance mechanisms in addition to transporter expression. 279 Furthermore, zosuquidar did not increase the efficacy of doxorubicin-loaded HSA(100%) and 280 HSA(200%) nanoparticles and only modestly enhanced the efficacy of doxorubicin-loaded 281 HSA(40%) nanoparticles. Together, these data confirm that administration of doxorubicin as 282 HSA nanoparticles resulted in the circumvention of ABCB1-mediated drug efflux. The 283 difference between HSA(40%) nanoparticles and the other two preparations may be explained 284 by elevated drug release due to the lower degree of cross-linking. 285
Interestingly, high concentrations of the crosslinker glutaraldehyde did not affect the efficacy 286 of the resulting doxorubicin-loaded nanoparticles although high glutaraldehyde concentrations 287 might have been expected to affect drug release and/ or to bind covalently to doxorubicin via 288 its amino group. 289
Notably, the results differ from a recent similar study in which nanoparticles prepared from 290 poly(lactic-co-glycolic acid) (PLGA) or polylactic acid (PLA), two other biodegradable 291 materials approved by the FDA and EMA for human use [32,33], did not bypass ABCB1-292 mediated drug efflux [34] . Differences in the mode of uptake and cellular distribution of 293 nanoparticles from different materials may be responsible for these discrepancies. HSA 294 nanoparticles may be internalised upon interaction with cellular albumin receptors [35, 36] . 295
Notably, nab-paclitaxel, an HSA nanoparticle-based preparation of paclitaxel (another ABCB1 296 substrate [26]), which is approved for the treatment of different forms of cancer [37], had 297 previously been shown not to avoid ABCB1-mediated drug efflux [38] . However, nab-298 paclitaxel is not produced by the use of crosslinkers, and the interaction of paclitaxel with 299 albumin may differ from that of doxorubicin. Hence, variations in drug binding and drug release 300 kinetics may be responsible for this difference. 301
Despite the prominent role of ABCB1 as a drug resistance mechanism, attempts to exploit it as 302 drug target have failed so far, despite the development of highly specific allosteric ABCB1 303 inhibitors (of which zosuquidar is one) [5, 26] . A number of reasons seem to account for the 304 clinical failure of ABCB1 inhibitors. ABCB1 is expressed at various physiological borders and 305 involved in the control of the body distribution of its many endogenous and exogenous 306 substrates. Systemic ABCB1 inhibition can therefore result in toxicity as consequence of a 307 modified body distribution of anti-cancer drugs (and other drugs that are co-administered for 308 other conditions than cancer), xenobiotics, and other molecules. In addition, cancer cells may 309 be characterised by multiple resistance mechanisms (including the expression of multiple 310 reporters) and targeting just one transporter may not be sufficient to overcome resistance (as 311 supported by our current finding that UKF-NB-3 r DOX 20 cells cannot be fully re- 
